SCHEMBL17693603

SCHEMBL17693603

COC(=O)C(=Cc1ccc(OP(=O)=O)c(C)c1)NC(=O)OCc1ccccc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.40
ALDH1A1 P00352 3/20 0.40
HPGD P15428 2/20 0.40
LMNA P02545 2/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40
KMT2A Q03164 2/20 0.39
MEN1 O00255 1/20 0.39
MIF P14174 1/20 0.37
AAK1 Q2M2I8 1/20 0.36
CA12 O43570 2/20 0.36
CA9 Q16790 2/20 0.36
CA4 P22748 1/20 0.36
CA6 P23280 1/20 0.36
CA5A P35218 1/20 0.36
CA7 P43166 1/20 0.36
CA14 Q9ULX7 1/20 0.36
CA5B Q9Y2D0 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17693653 0.91 NPC1 (0.40) KDM4EALDH1A1LMNASMN1; SMN2NPC1
SCHEMBL17693625 0.83 KDM4E (0.40) KDM4EALDH1A1HPGDLMNASMN1; SMN2
SCHEMBL5893113 0.83 MEN1 (0.43) KDM4EALDH1A1HPGDLMNASMN1; SMN2
SCHEMBL13756220 0.81 NPC1 (0.47) LMNASMN1; SMN2NPC1RAB9AKMT2A
SCHEMBL178749 0.81 NPC1 (0.47) LMNASMN1; SMN2NPC1RAB9AKMT2A
SCHEMBL13906649 0.80 CA12 (0.47) ALDH1A1LMNASMN1; SMN2NPC1RAB9A
SCHEMBL14623158 0.80 MMP1 (0.43) KDM4EALDH1A1HPGDLMNASMN1; SMN2
SCHEMBL17693641 0.79 AAK1 (0.39) KDM4EALDH1A1HPGDLMNASMN1; SMN2
SCHEMBL28979060 0.78 CA12 (0.45) KDM4EALDH1A1HPGDLMNASMN1; SMN2
SCHEMBL6638007 0.78 NPC1 (0.47) KDM4EALDH1A1HPGDLMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240024338-A1 CARBIDOPA AND L-DOPA PRODRUGS AND METHODS OF USE ABBVIE INC (US) 2024-01-25 US disclosed
US-20180079762-A1 Carbidopa and L-Dopa Prodrugs and Methods of use ABBVIE INC. (US) 2018-03-22 US disclosed
US-20160362431-A1 Carbidopa And L-Dopa Prodrugs And Methods Of Use ABBVIE INC. 2016-12-15 US disclosed
US-9446059-B2 Carbidopa and L-dopa prodrugs and methods of use ABBVIE INC. (US) 2016-09-20 US disclosed
US-20160106765-A1 Carbidopa and L-Dopa Prodrugs and Methods of Use ABBVIE INC. 2016-04-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160362431-A1 Carbidopa And L-Dopa Prodrugs And Methods Of Use COMT, SNCA, PARK7 KDM4E 3728/4885ALDH1A1 694/4885HPGD 206/4885
US-20160106765-A1 Carbidopa and L-Dopa Prodrugs and Methods of Use COMT, SNCA, PARK7 KDM4E 3728/4885ALDH1A1 694/4885HPGD 206/4885
US-20240024338-A1 CARBIDOPA AND L-DOPA PRODRUGS AND METHODS OF USE COMT, SNCA, PARK7 KDM4E 3728/4885ALDH1A1 694/4885HPGD 206/4885
US-20180079762-A1 Carbidopa and L-Dopa Prodrugs and Methods of use COMT, SNCA, PARK7 KDM4E 3728/4885ALDH1A1 694/4885HPGD 206/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.